Isofol Medical

0.67 SEK

-0.74 %

Less than 1K followers

ISOFOL

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Dividend

Investor consensus

Compare

-0.74 %

+1.67 %

-6.94 %

-8.09 %

-3.67 %

-61.69 %

+16.76 %

-94.17 %

-95.03 %

Isofol Medical is a research-based biotechnology company working to improve the prognosis of patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the effect of first-line standard treatment that is used globally for several forms of solid tumors. Isofol is conducting clinical development of arfolitixorin in colorectal cancer, the world's third most common cancer, where the medical need for better treatments is great.

Market cap

214.73M SEK

Turnover

288.67K SEK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

19.5.

2026

General meeting '26

19.5.

2026

Interim report Q1'26

25.8.

2026

Interim report Q2'26

All

Webcasts

Press releases

3rd party

ShowingAll content types

Regulatory press release4/15/2026, 2:00 PM

Notice to attend the Annual General Meeting held on May 19, 2026 in Isofol Medical AB (publ)

Isofol Medical

Press release4/15/2026, 7:10 AM

Isofol optimizes the design of its phase Ib/II study following new regulatory approval

Isofol Medical

Regulatory press release4/10/2026, 6:00 AM

Isofol Medical AB (publ) publishes annual report and corporate governance report for 2025

Isofol Medical

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Create account

Regulatory press release3/31/2026, 3:00 PM

Isofol receives gross proceeds of 18.9 MSEK in connection with the exercise of warrants and guarantee commitments for warrants of series TO1, and resolves on a directed share issue

Isofol Medical

Regulatory press release3/18/2026, 12:50 PM

Isofol secures license rights for arfolitixorin in autism

Isofol Medical

Regulatory press release3/13/2026, 5:40 PM

The subscription price for warrants of series TO1 in Isofol has been set at SEK 0.48 and the exercise period commences on 16 March 2026

Isofol Medical

Regulatory press release3/11/2026, 2:30 PM

Isofol receives top guarantee commitment and letters of intent corresponding to 42 percent of upcoming warrant exercise

Isofol Medical

Regulatory press release3/9/2026, 10:00 AM

Isofol’s Nomination Committee proposes election of Christian Haglund as new Board Director

Isofol Medical

Press release3/3/2026, 7:30 AM

Isofol presents at investor meetings in March

Isofol Medical

Third party research2/25/2026, 6:22 AM

Isofol Medical: From first lessons to second execution - ABG

* Strong early efficacy signal * Solid cost management * Fair value range of SEK 0.1-10.5/share Strong early efficacy signal Isofol today announced that all six currently evaluable RAS-mutated metastatic colorectal cancer patients in Part 1 of its Phase...

Isofol Medical

Regulatory press release2/24/2026, 8:32 AM

Isofol provides update on the ongoing phase Ib/II clinical study of arfolitixorin

Isofol Medical

Press release2/19/2026, 8:36 AM

Redeye: Isofol Medical (Q4 Review): Translational year ahead

Isofol Medical

Regulatory press release2/18/2026, 6:30 AM

Isofol Medical AB (publ) publishes year-end report, January – December 2025

Isofol Medical

Third party research1/15/2026, 12:46 PM

Isofol Medical: Learn from the first, deliver on the second - ABG

* Targeting a huge unmet medical need * Revised best-in-class potential * Fair value range of SEK 0.1-10.5/share Huge unmet medical needIsofol is developing arfolitixorin, a next-generation active folate designed to enhance standard chemotherapy built...

Isofol Medical

Press release1/9/2026, 6:30 AM

Isofol Medical

0.67 SEK

-0.74 %

Revenue and EBIT-%

EPS and dividend

Financial calendar

Notice to attend the Annual General Meeting held on May 19, 2026 in Isofol Medical AB (publ)

Isofol optimizes the design of its phase Ib/II study following new regulatory approval

Isofol Medical AB (publ) publishes annual report and corporate governance report for 2025

Join Inderes community

FREE account

PREMIUM account

Isofol receives gross proceeds of 18.9 MSEK in connection with the exercise of warrants and guarantee commitments for warrants of series TO1, and resolves on a directed share issue

Isofol secures license rights for arfolitixorin in autism

The subscription price for warrants of series TO1 in Isofol has been set at SEK 0.48 and the exercise period commences on 16 March 2026

Isofol receives top guarantee commitment and letters of intent corresponding to 42 percent of upcoming warrant exercise

Isofol’s Nomination Committee proposes election of Christian Haglund as new Board Director

Isofol presents at investor meetings in March

Isofol Medical: From first lessons to second execution - ABG

Isofol provides update on the ongoing phase Ib/II clinical study of arfolitixorin

Redeye: Isofol Medical (Q4 Review): Translational year ahead

Isofol Medical AB (publ) publishes year-end report, January – December 2025

Isofol Medical: Learn from the first, deliver on the second - ABG

Isofol participates in the ASCO GI congress

BioStock: Back on track: 2025 was a year of clinical progress for Isofol, which restarted studies with arfolitixorin

Isofol participates in several investor meetings in December and January

BioStock: European Patent Office gives green light for Isofol’s arfolitixorin

BioStock: Isofol reaches new phase Ib/II milestones in Europe – prepares Japanese study with Solasia

European Patent Office intends to grant a new patent for Isofol’s arfolitixorin